The development of the dosage form with L-carnitine for children

Authors

  • O. M. Bezchasnyuk National University of Pharmacy, Ukraine
  • T. V. Zborovska National University of Pharmacy, Ukraine
  • S. M. Kovalenko National University of Pharmacy, Ukraine

DOI:

https://doi.org/10.24959/nphj.14.1927

Keywords:

manufacture of dosage forms for children, L-carnitine, syrup

Abstract

Treatment of metabolic disorders in children and adults of all ages is the current serious problem. Nowadays much attention is paid to the treatment with drugs based on L-carnitine. The drug for children in the form of a syrup containing L-carnitine has been researched and developed. Drugs with the dosed L-carnitine for children are absent at the modern pharmaceutical market of Ukraine. Suitable dosage forms for children of all ages are liquid forms, including syrups. The drug technology has been developed and tested in the academic research technological laboratory of the National University of Pharmacy for introduction into the pharmaceutical industry of the country. To develop this technology the literature has been analyzed; a number of similar drugs has been identified and their qualitative composition has been studied. The quantitative composition of the drug developed has been determined experimentally. Based on the data of the pharmacological activity of L-carnitine the concentration of the active substance has been selected. The preservatives, modifiers of acidbase properties and flavours have been selected. The sequence of manufacturing operations, which allows creating a quality product, has been determined. A stepwise manufacture of the drug in the flowchart of the technological process has been described. The pharmacotechnological quality characteristics of the medicinal dosage form proposed, namely the drug appearance, pH, relative density and transparency of the resulting solution, have been studied. The results of this work have been included in the pharmaceutical development of the drug.

References

Брин И.Л. // Вестник педиатр. фармакол. и нутрициол. – 2006. – №2. – С. 32-39.

Державна фармакопея України / Державне підриємство «Науково-експертний фармакопейний центр». – 1-е вид. – Х.: РІРЕГ, 2001. – 556 с.

Компендіум 2008 – лікарські препарати: в 2-х т. / За ред. В.М.Коваленка, О.П.Вікторова. – К.: Моріон, 2008. – Т. 1. – 1128 с.; Т. 2. – 1126 с.

Перелік допоміжних речовин, дозволених для застосування у виробництві лікарських засобів, які (лікарські засоби) реєструються в Україні: Наказ МОЗ України від 15.01.2003 р. №8. – К., 2003. – 47 с.

Чуєшов В.І., Хохлова Л.М., Ляпунова О.О. та ін. Технологія ліків промислового виробництва: Підруч. / За ред. В.І.Чуєшова. – Х.: Вид-во НФаУ; Золоті сторінки, 2003. – 720 с.

Яковлева Л.В. // Укр. журн. клин. и лабораторной медицины. – 2011. – Т. 6, №2. – С. 17-24.

Bohmer T., Rynding A., Solberg H. // Clin. Chim. Acta. – 1974. – №57. – P. 55-61.

Feller A.G., Rudman D. // J. of Nutrition. – 1988. – Vol. 118. – P. 541-547.

Harmeyer J. // Lohmann Information. – 2002. – №27. – P. 1-8.

Meier J. D-Carnitin, harmlos? In Carnitin in der Medizin / R.Gitzelmann, K.Baerlocher & B. Steinmann (eds.). – Stuttgart: Schattauer, 1987. – Р. 101-104.

Rebouche C.J., Paulson D.J. // Ann. Rev. Nutr. – 1986. – №6. – P. 41-46.

Salvioli G., Neri M. // Drugs Exptl. Clin. Res. – 1994. – Vol. 20 (4). – Р. 169-176.

Sinatra S., Sinatra J. L-Carnitine and the Heart. – 1999. – 64 р.

Witte K.K., Clark A.L. // Heart Fail Rev. – 2006. – №11 (1). – P. 65-74.

Downloads

Published

2014-03-06

Issue

No. 1(77) (2014)

Section

Technology of Medicines

License

Copyright (c) 2014 National University of Pharmacy

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Authors who publish with this journal agree to the following terms:

  1. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
  2. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
  3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).